Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by houbahopon Jan 03, 2011 10:19am
268 Views
Post# 17917906

RE: RE: RE: Year End Results...

RE: RE: RE: Year End Results...I won't hide I also feel deceived by TH sp performance. But most of it, I acknowledge, because of people at the FDA slowing down the approval process.

On Theratechnologies side, my main concern is their lack of transparency on the value of their product. The last two press releases didn't mention the sale price and, in my opinion, they did not because making it public would have been damaging for the value of the share price.

Unless they want to hide a good news for some other reasons (takeover by Serono?), but I doubt it.

In my opinion, Theratechnologies' (and the analysts) valuation of the cost of the treatment to fight lypo is out of whack with reality and they are hiding this fact.

I also have missed some other opportunities elsewhere in 2010 because I had too much tied to TH. I have reduced by a third my position last Summer and I am hanging on the rest because I also believe we'll see in $8. And like lmz, i won't spit on 50% expected return!

All the Best for 2011,


Marsupilami
Bullboard Posts